| 期刊全稱(chēng) | Biomarker Methods in Drug Discovery and Development | | 影響因子2023 | Feng Wang | | 視頻video | http://file.papertrans.cn/188/187791/187791.mp4 | | 發(fā)行地址 | Broad coverage of proven and practical biomarker techniques currently applied in drug discovery and development.Multiple biomarker analysis methods for each of the different molecular levels.Real biom | | 學(xué)科分類(lèi) | Methods in Pharmacology and Toxicology | | 圖書(shū)封面 |  | | 影響因子 | The pharmaceutical industry has faced many significant challenges since the early 1990s. The fundamental issue that needs to be addressed is how to improve the efficiency of drug discovery and development. The current research and development (R&D) cost for developing a new therapeutic drug is greater than $800 million. Additionally, it takes an average of 12 years to get a new drug to market with an attrition rate greater than 90%. Reviewing the overall pharmaceutical R&D process, it has become clear that many of the drug failures are due to our lack of knowledge in population diversity, which is responsible for differences in drug efficacy and toxicity. In fact, not a single approved drug is 100% safe and efficacious for all patients. For researchers, the key question is: How can we discover biomarkers that can be used to distinguish patients who will respond to the drug without adverse effects from those who will not respond and/or will have adverse effects? There is tremendous urgency to address this question. Biomarkers also fit perfectly with the vision of personalized medicine, the new expectation of medical practice. This is why biomarker research has been a central focus i | | Pindex | Book 2008 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國(guó)際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-16 20:17
發(fā)表于 2025-3-21 18:01:18
